课题基金 / 基金详情

IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS

IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS
伊班膦酸钠治疗骨质疏松症 3 年
批准号：
6291200
负责人：
C. CONRAD JOHNSTON
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6291200
关键词：
bone density bone fracture clinical research diphosphonate drug adverse effect drug screening /evaluation female human subject human therapy evaluation intravenous administration longitudinal animal study osteoporosis placebos postmenopause skeletal disorder chemotherapy vertebrae women's health

项目摘要

项目成果

C. CONRAD JOHNSTON的其他基金

相似基金

相关文献

中文摘要
翻译
这项为期三年的第三阶段研究的目的是通过以新的脊椎骨折发生率为主要终点来评估间歇静脉治疗的有效性和安全性，从而探讨伊班磷酸钠在绝经后骨质疏松症长期治疗中的疗效。具体目标是：确定伊班磷酸钠是否能预防绝经后骨质疏松症患者的骨折和骨质丢失。以确定与静脉注射相关的副作用的类型。用伊班磷酸钠测定治疗后血中伊班磷酸钠的含量并估算药物在血液中的停留时间
英文摘要
The purpose of this three year phase III study is to investigate the therapeutic effect of ibandronate in the long-term treatment of postmenopausal osteoporosis by evaluating the efficacy and safety of intermittent intravenous treatment using the incidence of new vertebral fractures as the primary endpoint. The specific objectives are: To determine whether Ibandronate prevents fractures and bone loss in women with established postmenopausal osteoporosis. To determine the type of side effects associated with the i.v. administration of Ibandronate To determine the amount of Ibandronate in the blood following treatment and to estimate how long the drug stays in the blood
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ROLE OF SEX STEROIDS IN AGE-RELATED BONE LOSS
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS
海外基金